ALS

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

New DDW Highlights vodcast: 17 September 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week, DDW has opened… Read More

#News

#ALS #Brain #Dementia #Neurodegenerative disorders #Neuroscience

This week in drug discovery (9-13 September) 

News round-up for 9-13 September by DDW Senior Digital Content Editor Diana Spencer. This week, DDW has opened registrations for its webinar ‘The latest advancements driving neuroscience drug discovery research’, so our news highlights focus on developments in neuroscience, including a novel drug that has… Read More

#News

#ALS #Autism #Neurology #Neuroscience #Schizophrenia

This week in drug discovery (1-5 April) 

News round-up for 1-5 April by DDW Digital Content Editor Diana Spencer. This has been a busy week in the field of neuroscience drug discovery, with EU approval for a long-acting schizophrenia treatment, research revealing new insights into autism, the formation of a partnership focused on ALS drug… Read More

#News

Neuron
#ALS #Human disease models #iPSC #Neurology #Pluripotent stem cells #Stem cells #Whitepaper

Whitepaper: Explore iPSC-derived motor neuron morphology

A new whitepaper is now available from DDW and Sartorius entitled ‘iPSC-Derived Motor Neurons and Microglia From ALS Background Display Disease Phenotype’. Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients… Read More

#News

#ALS #Drug discovery #Human disease models #iPSC #Neurology #Pluripotent stem cells #Stem cells

Using patient-specific cells for disease modelling

Induced pluripotent stem cell (iPSC)-derived cells are a significant resource for disease modelling. They allow the use of cells directly from affected patients and have the potential to guide these cells towards multiple lineages. Download the whitepaper to: Explore iPSC-derived motor neuron morphology Discover how ALS disease phenotype… Read More

#Resources

AI clinical trials concept
#AI / data analytics / healthtech / informatics #ALS #Artificial intelligence (AI) #Verge Genomics #Wearable tech

AI-discovered ALS drug trial uses unique remote monitoring

Verge Genomics has initiated a Phase Ib proof-of-concept study for the treatment of sporadic and familial forms of amyotrophic lateral sclerosis (ALS) with VRG50635. VRG50635 is a small molecule PIKfyve inhibitor and is reportedly one of the first drugs to enter clinical trials that was entirely… Read More

#Editor's Choice #News

Demyelination of neuron
#ALS #Drug repurposing #LifeArc #Medicines Discovery Catapult #MND Association #Motor neurone disease #Neuroscience

New guiding principles to overcome barriers to MND drug discovery

New guidance for the motor neuron disease (MND) drug discovery community has been published to ensure that future drug discovery and development efforts have the best chance of successfully translating from the lab to the clinic. The whitepaper ‘Guiding principles for drug discovery and development in… Read More

#News #Trending News

Autophagy
#ALS #Autophagy #Healthspan #Neurodegenerative disorders #Parkinson's #Turning Science into Business

Turning Science into Business: Inducing autophagy to treat disease

DDW’s Diana Spencer speaks to Peter Hamley, Chief Scientific Officer of Samsara Therapeutics, to understand the role autophagy plays in neurodegenerative diseases and how boosting this process could increase healthspan. DS: Samsara’s autophagy inducing candidate SAM001 will be the first agent of its class to enter clinical trials. What is… Read More

#Exclusive Content

Hormones in the brain concept
#ALS #Bloom Science #Clinical trial #Phase I trial #Rare disease

Early trial success for Dravet syndrome and ALS therapeutic

Bloom Science has announced positive topline data from a Phase I clinical trial of BL-001, a potential first-in-class therapeutic the company is developing for Dravet syndrome and amyotrophic lateral sclerosis (ALS). In the trial, BL-001 demonstrated a favourable safety profile and was well… Read More

#News

Biogen head office
#ALS #Alzheimer's #Biogen #Business #Investment #Mergers and acquisitions

Biogen acquires Reata and cuts 1,000 jobs

Biogen has revealed an agreement to acquire Reata Pharmaceuticals for approximately $7.3 billion. The news follows an announcement by the company last week that it would cut around 1,000 jobs, or 11% of its workforce, to allow investment into its product pipeline. In its second quarter results, the company said… Read More

#Business & Investment #News #Trending News

Neurons
#ALS #LifeArc #MND #Motor neurone disease #University of Edinburgh

Project to test drug combinations for motor neuron disease

A new project by researchers in Edinburgh aims to identify combinations of existing drugs that could be used together to treat motor neuron disease (MND). Led by Prof Siddharthan Chandran, the £3.3 million project is funded by the medical research charity LifeArc, as part of an… Read More

#News

#AI #ALS #BenevolentAI #Drug discovery

BenevolentAI progresses drug for the potential treatment of ALS 

BenevolentAI, developers of AI that accelerates biopharma discovery, has delivered BEN-34712, its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS).  BEN-34712 is an oral, potent and selective brain penetrant RARɑ𝛃 (retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug… Read More

#News

#ALS #LifeArc #Neuroscience #Partnership #Precision medicine #PrecisionLife

Partners to advance precision medicines for MND

Not-for-profit medical research organisation LifeArc and techbio company PrecisionLife have agreed a strategic R&D collaboration to accelerate the discovery of targeted treatments for motor neurone disease (MND). MND is also known as amyotrophic lateral sclerosis (ALS) and Lou Gehrig’s disease. The collaboration will accelerate… Read More

#News

#ALS #Cerevance #Financing #Funding #Neurology #Parkinson's #Schizophrenia

$116 million financing will support neurological disease trials

Cerevance has expanded its Series B funding round with an additional close of $51 million, bringing the total to $116 million.  The financing will support upcoming clinical trials focused on Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), and schizophrenia.   “We are thrilled to secure additional funding from world-class investors who strongly… Read More

#Business & Investment #News

AI brain
#AI / data analytics / healthtech / informatics #ALS #Biotechnology #Clinical trials #Drug discovery #Genomics

AI-driven biotech initiates Phase I trial for ALS drug 

Verge Genomics, a clinical-stage, tech-enabled biotechnology company using artificial intelligence (AI) and human data to transform drug discovery, has announced today that the first subject has been dosed in a Phase I clinical trial of VRG50635 for amyotrophic lateral sclerosis (ALS).  VRG50635 is a small molecule inhibitor… Read More

#News

#ALS #Alzheimer's #Biomarkers #Breast cancer #Cell and gene therapy #Head and neck cancer #Ice Bucket Challenge #Manufacturing #Neurodegenerative disorders #Oncology #Ophthalmology

This week in drug discovery (3-7 October)

News round-up for 3-7 October by DDW Digital Content Editor Diana Spencer This week has brought new trial results and regulatory approvals shedding light and bringing hope into therapy areas of unmet need. The University of Birmingham and… Read More

#News